NASDAQ:EXAS Exact Sciences (EXAS) Stock Forecast, Price & News $81.58 +0.44 (+0.54%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$79.69▼$81.6650-Day Range$62.68▼$83.6152-Week Range$29.27▼$85.82Volume1.69 million shsAverage Volume2.24 million shsMarket Capitalization$14.72 billionP/E RatioN/ADividend YieldN/APrice Target$79.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exact Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside3.0% Downside$79.13 Price TargetShort InterestHealthy5.44% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment1.10Based on 10 Articles This WeekInsider TradingSelling Shares$3.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.16) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector379th out of 1,006 stocksMedical Laboratories Industry11th out of 24 stocks 2.3 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.13, Exact Sciences has a forecasted downside of 3.0% from its current price of $81.58.Amount of Analyst CoverageExact Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.44% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Exact Sciences has recently decreased by 11.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 77.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private colorectal cancer diagnostics services" product. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.82. Previous Next 3.9 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Exact Sciences this week, compared to 6 articles on an average week.Search Interest40 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.MarketBeat Follows9 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,320,986.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions90.30% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($2.16) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exact Sciences (NASDAQ:EXAS) StockEXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.Read More Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesMay 20, 2023 | marketbeat.comMarketBeat Week in Review – 5/15 - 5/19 (EXAS)Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunitiesMay 15, 2023 | marketbeat.comExact Sciences Serves Investors Exactly What They Wished For Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. TheMay 31, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 30, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Exact Sciences (EXAS)May 28, 2023 | fool.comExact Sciences (NASDAQ: EXAS)May 26, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Exact Sciences Co. (NASDAQ:EXAS) Raised by AnalystMay 23, 2023 | finance.yahoo.comExact Sciences (EXAS) Gains From New Buyouts Amid High CostsMay 22, 2023 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Receives $80.40 Consensus Price Target from BrokeragesMay 31, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 18, 2023 | finance.yahoo.comShould You Invest in Exact Sciences Corporation (EXAS) Now?May 17, 2023 | finance.yahoo.comEXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGSMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Exact Sciences (EXAS)May 17, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) PT Raised to $80.00 at Piper SandlerMay 16, 2023 | proactiveinvestors.comExact Sciences positioned for a solid year after ‘impressive’ 1Q, broker saysMay 15, 2023 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Insider Sells $400,000.00 in StockMay 14, 2023 | finance.yahoo.comA Bull Market Is Coming: 1 Supercharged Growth Stock to Buy Hand Over Fist Before It Soars 164%, According to Wall StreetMay 14, 2023 | americanbankingnews.comJames Herriott Sells 1,300 Shares of Exact Sciences Co. (NASDAQ:EXAS) StockMay 14, 2023 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Expected to Post Q2 2023 Earnings of ($0.51) Per ShareMay 13, 2023 | americanbankingnews.comStifel Nicolaus Raises Exact Sciences (NASDAQ:EXAS) Price Target to $85.00May 12, 2023 | benzinga.comCheck Out What Whales Are Doing With EXASMay 12, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Releases Earnings Results, Beats Estimates By $0.37 EPSMay 12, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Price Target Raised to $100.00May 12, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Reaches New 52-Week High After Earnings BeatMay 11, 2023 | msn.comCitigroup Maintains Exact Sciences (EXAS) Buy RecommendationMay 11, 2023 | finance.yahoo.comWhy Exact Sciences Stock Roared Higher This WeekMay 11, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Price Target Raised to $90.00May 11, 2023 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Price Target Raised to $99.00See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Company Calendar Last Earnings5/09/2023Today5/31/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,400Year Founded1995Price Target and Rating Average Stock Price Forecast$79.13 High Stock Price Forecast$100.00 Low Stock Price Forecast$60.00 Forecasted Upside/Downside-2.5%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-623,510,000.00 Net Margins-23.49% Pretax Margin-23.73% Return on Equity-16.64% Return on Assets-8.18% Debt Debt-to-Equity Ratio0.77 Current Ratio2.97 Quick Ratio2.63 Sales & Book Value Annual Sales$2.08 billion Price / Sales7.03 Cash FlowN/A Price / Cash FlowN/A Book Value$16.94 per share Price / Book4.79Miscellaneous Outstanding Shares180,480,000Free Float178,129,000Market Cap$14.64 billion OptionableOptionable Beta1.41 Social Links Key ExecutivesKevin T. ConroyChairman, President & Chief Executive OfficerJeffrey Thomas ElliottExecutive VP, Chief Operating & Financial OfficerSandra StatzSenior VP-Clinical & Regulatory AffairsPaul J. LimburgCo-Chief Medical Officer & ScreeningFrederick BaehnerCo-Chief Medical Officer & Precision OncologyKey CompetitorsQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHNateraNASDAQ:NTRARevvityNYSE:RVTYRevvityNYSE:PKIView All CompetitorsInsiders & InstitutionsToroso Investments LLCBought 6,721 shares on 5/23/2023Ownership: 0.004%Capital Impact Advisors LLCSold 1,609 shares on 5/23/2023Ownership: 0.003%American TrustSold 125 shares on 5/22/2023Ownership: 0.002%New York State Common Retirement FundSold 112,776 shares on 5/18/2023Ownership: 0.218%JPMorgan Chase & Co.Sold 25,800 shares on 5/18/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EXAS Stock - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price forecast for 2023? 13 Wall Street analysts have issued 12-month price targets for Exact Sciences' stock. Their EXAS share price forecasts range from $60.00 to $100.00. On average, they anticipate the company's stock price to reach $79.13 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2023? Exact Sciences' stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 63.9% and is now trading at $81.13. View the best growth stocks for 2023 here. Are investors shorting Exact Sciences? Exact Sciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 9,810,000 shares, a decrease of 11.7% from the April 30th total of 11,110,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the days-to-cover ratio is currently 4.7 days. View Exact Sciences' Short Interest. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.37. The medical research company had revenue of $602 million for the quarter, compared to the consensus estimate of $543.18 million. Exact Sciences had a negative trailing twelve-month return on equity of 16.64% and a negative net margin of 23.49%. Exact Sciences's quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.04) earnings per share. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), Pinnacle Focused Opportunities ETF (FCUS), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA Healthcare Momentum ETF (PTH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.38 billion-$2.42 billion, compared to the consensus revenue estimate of $2.30 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). What is Exact Sciences' stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS." Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.38%), Baillie Gifford & Co. (2.66%), Sumitomo Mitsui Trust Holdings Inc. (2.12%), Nikko Asset Management Americas Inc. (1.83%), Ensign Peak Advisors Inc (1.58%) and Artisan Partners Limited Partnership (1.51%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Sarah Condella and Torsten Hoof. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exact Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $81.13. How much money does Exact Sciences make? Exact Sciences (NASDAQ:EXAS) has a market capitalization of $14.64 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. How many employees does Exact Sciences have? The company employs 6,400 workers across the globe. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More How can I contact Exact Sciences? Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701. This page (NASDAQ:EXAS) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.